Medicare AdvantageCoverageMedium impact
MA07.040c, Transcatheter Arterial Chemoembolization (TACE) of Hepatic Malignancies
Independence Blue Cross·Oncology, Gastroenterology, Radiology·Medical Policy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA07.040c for Transcatheter Arterial Chemoembolization (TACE) of Hepatic Malignancies has been reissued and will take effect March 5, 2025. This is an updated policy that may contain changes to coverage criteria, prior authorization requirements, or documentation standards for TACE procedures used to treat liver cancers.
Action Required
By March 5, 2025: Review the complete updated policy MA07.040c on the IBX website to identify any changes to coverage criteria, prior authorization requirements, or documentation standards for TACE procedures. Update billing workflows and provider documentation requirements accordingly for Medicare Advantage patients receiving hepatic malignancy treatments.